Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
William Powderly, Andrew Hill & Christiane Moecklinghoff. (2014) Is There a Higher Risk of CNS Adverse Events for PI Monotherapy Versus Triple Therapy? A Review of Results From Randomized Clinical Trials. HIV Clinical Trials 15:3, pages 79-86.
Read now
Read now
Antonio Rivero & Inés Pérez-Camacho. (2010) Does lopinavir/ritonavir alter the primary gingival epithelium?. Expert Review of Anti-infective Therapy 8:12, pages 1345-1349.
Read now
Read now
Articles from other publishers (40)
Laurent Hocqueloux, Camélia Gubavu, Thierry Prazuck, Barbara De Dieuleveult, Jérôme Guinard, Aymeric Sève, Catherine Mille, Elise Gardiennet, Pauline Lopez, Christine Rouzioux, Sandrine Lefeuvre & Véronique Avettand-Fènoël. (2020) Genital Human Immunodeficiency Virus–1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials. Clinical Infectious Diseases 70:9, pages 1973-1979.
Crossref
Crossref
Cassidy W. Claassen, David Keckich, Chidi Nwizu, Alash’le Abimiku, Donald Salami, Michael Obiefune, Bruce L. Gilliam & Anthony Amoroso. (2019) HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial. Journal of the International Association of Providers of AIDS Care (JIAPAC) 18, pages 232595821882320.
Crossref
Crossref
Juan Pasquau, Carmen Hidalgo-Tenorio, María Luisa Montes, Alberto Romero-Palacios, Jorge Vergas, Isabel Sanjoaquín, José Hernández-Quero, Koldo Aguirrebengoa, Francisco Orihuela, Arkaitz Imaz, María José Ríos-Villegas, Juan Flores, María Carmen Fariñas, Pilar Vázquez, María José Galindo, Isabel García-Mercé, Fernando Lozano, Ignacio de los Santos, Samantha Elizabeth de Jesus & Coral García-Vallecillos. (2018) High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLOS ONE 13:4, pages e0195068.
Crossref
Crossref
Maximilian Donath, Timo Wolf, Martin Stürmer, Eva Herrmann, Markus Bickel, Pavel Khaykin, Siri Göpel, Peter Gute, Annette Haberl, Philipp de Leuw, Gundolf Schüttfort, Annemarie Berger & Christoph Stephan. (2016) HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Medical Microbiology and Immunology 205:6, pages 575-583.
Crossref
Crossref
Kate El Bouzidi, Dami Collier, Eleni Nastouli, Andrew J. Copas, Robert F. Miller & Ravindra K. Gupta. (2016) Virological efficacy of PI monotherapy for HIV-1 in clinical practice. Journal of Antimicrobial Chemotherapy 71:11, pages 3228-3234.
Crossref
Crossref
Duncan Churchill, Laura Waters, Nadia Ahmed, Brian Angus, Marta Boffito, Mark Bower, David Dunn, Simon Edwards, Carol Emerson, Sarah Fidler, Martin Fisher, Rob Horne, Saye Khoo, Clifford Leen, Nicola Mackie, Neal Marshall, Fernando Monteiro, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Sarah Pett, Andrew Phillips, Frank Post, Anton Pozniak, Iain Reeves, Caroline Sabin, Roy Trevelion, John Walsh, Ed Wilkins, Ian Williams & Alan Winston. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine 17, pages s2-s104.
Crossref
Crossref
Miguel A. Lopez-Ruz, Purificación Navas, Miguel A. López-Zúñiga, María Carmen Gonzalvo, Antonio Sampedro, Juan Pasquau, Carmen Hidalgo-Tenorio, Rosario Javier & José A. Castilla. (2016) Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients. PLOS ONE 11:7, pages e0159305.
Crossref
Crossref
Laura Galli, Vincenzo Spagnuolo, Alba Bigoloni, Antonella D'Arminio Monforte, Francesco Montella, Andrea Antinori, Antonio Di Biagio, Stefano Rusconi, Giovanni Guaraldi, Simona Di Giambenedetto, Marco Borderi, Davide Gibellini, Giada Caramatti, Adriano Lazzarin & Antonella Castagna. (2016) Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. Journal of Antimicrobial Chemotherapy 71:6, pages 1637-1642.
Crossref
Crossref
JR Arribas, P-M Girard, N Paton, A Winston, A-G Marcelin, D Elbirt, A Hill & MB Hadacek. (2016)
Efficacy of protease inhibitor monotherapy
vs
. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials
. HIV Medicine 17:5, pages 358-367.
Crossref
Crossref
Nicholas I Paton, Wolfgang Stöhr, Lars Oddershede, Alejandro Arenas-Pinto, Simon Walker, Mark Sculpher & David T Dunn. (2016) The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technology Assessment 20:21, pages 1-158.
Crossref
Crossref
A. Torres-Cornejo, O.J. BenMarzouk-Hidalgo, P. Viciana, B. Sánchez, M.A. López-Ruz, L.F. López-Cortés & A. Gutiérrez-Valencia. (2016) Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract. Clinical Microbiology and Infection 22:1, pages 98.e7-98.e10.
Crossref
Crossref
Giovanni Guaraldi, André Fragoso Gomes & Ana Rita Silva. 2016. Managing the Older Adult Patient with HIV. Managing the Older Adult Patient with HIV
129
180
.
O.J. BenMarzouk-Hidalgo, A. Torres-Cornejo, A. Gutiérrez-Valencia, R. Ruiz-Valderas, P. Viciana, L.F. López-Cortés & G. Antonelli. (2014) Immune activation throughout a boosted darunavir monotherapy simplification strategy. Clinical Microbiology and Infection 20:12, pages 1297-1303.
Crossref
Crossref
Antonella Castagna, Vincenzo Spagnuolo, Laura Galli, Concetta Vinci, Silvia Nozza, Elisabetta Carini, Antonella D’Arminio Monforte, Francesco Montella, Andrea Antinori, Antonio Di Biagio, Stefano Rusconi & Adriano Lazzarin. (2014) Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. AIDS 28:15, pages 2269-2279.
Crossref
Crossref
Krittaecho Siripassorn, Suthat Chottanapund, Wisit Prasithsirikul & Weerawat Manosuthi. (2013) Ritonavir-Boosted Lopinavir as Maintenance Monotherapy in HIV-Infected Patients Who Achieved Viral Suppression during a Second-Line Protease Inhibitor–Based Regimen. Journal of the International Association of Providers of AIDS Care (JIAPAC) 13:4, pages 353-360.
Crossref
Crossref
A. Curran, P. Monteiro, P. Domingo, J. Villar, A. Imaz, E. Martinez, I. Fernandez, H. Knobel, D. Podzamczer, J. A. Iribarren, M. Penaranda, M. Crespo, A. Curran, E. Ribera, J. Navarro, M. Crespo, P. Monteiro, E. Martinez, I. Fernandez, P. Domingo, J. Villar, H. Knobel, A. Imaz, D. Podzamczer, M. Ibarguren, J. A. Iribarren, M. Penaranda & M. Riera. (2014) Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. Journal of Antimicrobial Chemotherapy 69:5, pages 1390-1396.
Crossref
Crossref
Jonathan Colasanti, Vincent C. Marconi & Babafemi Taiwo. (2014) Antiretroviral reduction. AIDS 28:7, pages 943-947.
Crossref
Crossref
Almudena Torres-Cornejo, Omar J. BenMarzouk-Hidalgo, Alicia Gutiérrez-Valencia, Pilar Pérez-Romero, Reyes Martín-Peña, Rosa Ruiz-Valderas, Pompeyo Viciana & Luis F. Lopez-Cortes. (2014) Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. AIDS 28:2, pages 201-208.
Crossref
Crossref
. (2014) 6.0 Supporting patients on therapy. HIV Medicine 15, pages 36-47.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Luis F. Lopez-Cortes, Rosa Ruiz-Valderas, Elena Sánchez-Rivas, Amparo Lluch, Alicia Gutierrez-Valencia, Almudena Torres-Cornejo, Omar J. BenMarzouk-Hidalgo & Pompeyo Viciana. (2013) Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy 57:8, pages 3746-3751.
Crossref
Crossref
Laura Waters, Loveleen Bansi, David Asboe, Anton Pozniak, Erasmus Smit, Chloe Orkin, Esther Fearnhill, David Dunn & Andrew Phillips. (2013) Second-Line Protease Inhibitor-Based Antiretroviral Therapy after Non-Nucleoside Reverse Transcriptase Inhibitor Failure: The Effect of a Nucleoside Backbone. Antiviral Therapy 18:2, pages 213-219.
Crossref
Crossref
Elena López Aspiroz, Salvador Enrique Cabrera Figueroa, Alfonso Domínguez-Gil Hurlé & María José García Sánchez. (2013) Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 31:1, pages 36-43.
Crossref
Crossref
Tomasz Mikuła, Magdalena M. Dąbrowska, Joanna Kozłowska & Alicja Wiercińska-Drapało. (2013) Zmiana terapii antyretrowirusowej. HIV & AIDS Review 12:4, pages 113-115.
Crossref
Crossref
Elena Reina, Ramón San Miguel, Natalia Larrea, Patricia Garcia & Victor Napal. (2012) Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy. International Journal of Clinical Pharmacy 34:6, pages 911-916.
Crossref
Crossref
Marguerite Guiguet, Jade Ghosn, Claudine Duvivier, Jean-Luc Meynard, Guillaume Gras, Marialuisa Partisani, Elina Teicher, Aba Mahamat, Franck Rodenbourg, Odile Launay & Dominique Costagliola. (2012) Boosted protease inhibitor monotherapy as a maintenance strategy. AIDS 26:18, pages 2345-2350.
Crossref
Crossref
. (2012) 6.0 Supporting patients on therapy. HIV Medicine 13, pages 35-46.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Miriam Estébanez & Jose R. Arribas. (2012) Protease Inhibitor Monotherapy: What Is Its Role?. Current HIV/AIDS Reports 9:2, pages 179-185.
Crossref
Crossref
Weerawat Manosuthi, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi & Somnuek Sungkanuparph. (2012) Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure. AIDS Research and Therapy 9:1, pages 8.
Crossref
Crossref
L. González Rivas, E. Sánchez Gómez, R. Sánchez del Moral, S. Grutzmancher Saiz, E. Pujol de la Llave & C. Bocanegra Martín. (2011) Simplification of Antiretroviral Therapy: A Good Choice for Our Patients and the Sustainability of Our Health Care System. Farmacia Hospitalaria (English Edition) 35:6, pages 317-321.
Crossref
Crossref
L. González Rivas, E. Sánchez Gómez, R. Sánchez del Moral, S. Grutzmancher Saiz, E. Pujol de la Llave & C. Bocanegra Martín. (2011) Simplificación del tratamiento antirretroviral: una buena alternativa para nuestros pacientes y para la sostenibilidad de nuestro sistema sanitario. Farmacia Hospitalaria 35:6, pages 317-321.
Crossref
Crossref
Pedro Cahn, Julio Montaner, Patrice Junod, Patricia Patterson, Alejandro Krolewiecki, Jaime Andrade-Villanueva, Isabel Cassetti, Juan Sierra-Madero, Arnaldo David Casiró, Raul Bortolozzi, Sergio Horacio Lupo, Nadia Longo, Emmanouil Rampakakis, Nabil Ackad & John S. Sampalis. (2011) Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen. PLoS ONE 6:8, pages e23726.
Crossref
Crossref
Sandra Mathis, Bettina Khanlari, Federico Pulido, Mauro Schechter, Eugenia Negredo, Mark Nelson, Pietro Vernazza, Pedro Cahn, Jean-Luc Meynard, Jose Arribas & Heiner C. Bucher. (2011) Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. PLoS ONE 6:7, pages e22003.
Crossref
Crossref
John E McKinnon, Rafael Delgado, Federico Pulido, Wei Shao, Jose R Arribas & John W Mellors. (2011) Single Genome Sequencing of HIV-1 Gag and Protease Resistance Mutations at Virologic Failure during the Ok04 Trial of Simplified versus Standard Maintenance Therapy. Antiviral Therapy 16:5, pages 725-732.
Crossref
Crossref
Cecilia Pizzocolo, Antonella Castagna & Adriano Lazzarin. (2011) HIV protease inhibitors: present and future. Future Virology 6:5, pages 571-580.
Crossref
Crossref
Estevão Portela Nunes, Marilia Santini de Oliveira & Beatriz Grinsztejn. (2011) Lopinavir: the old champion. Future Virology 6:5, pages 561-570.
Crossref
Crossref
Ignacio Pérez-Valero & Jose R Arribas. (2011) Protease inhibitor monotherapy. Current Opinion in Infectious Diseases 24:1, pages 7-11.
Crossref
Crossref
J.-L. Meynard, V. Bouteloup, R. Landman, P. Bonnard, V. Baillat, A. Cabie, S. Kolta, J. Izopet, A.-M. Taburet, P. Mercie, G. Chene & P.-M. Girard. (2010) Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. Journal of Antimicrobial Chemotherapy 65:11, pages 2436-2444.
Crossref
Crossref
Stephen Taylor & Sophia Davies. (2010) Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Current Opinion in HIV and AIDS 5:4, pages 335-343.
Crossref
Crossref